Twenty percent of patients on Victoza had nausea, 11% had vomiting, and 13% had diarrhea.
But the twice-a-day Byetta is already facing competition from Victoza, a once-a-day injection from insulin giant Novo Nordisk.
Another GLP-1 analog is liraglutide, sold by Nova Nordisk (NYSE:NVO) as Victoza.
FORBES: Diabetes Market Booms As Substitutes Sought For Daily Insulin Dosing
Victoza's label also has a warning about the potential risk of thyroid tumors.
WSJ: FDA Approves Amylin's Bydureon Diabetes Drug After Delays
Another worry, raised by studies of Victoza in rats, is that these drugs might be linked to rare thyroid cancers.
As with Victoza, there is also a REMS ( read the label).
FORBES: And They're Off: Amylin And Novo Nordisk Begin Their Battle
This is disastrous, because it is going to give a competitor, Victoza from Novo Nordisk, time to gain market share and become entrenched.
Aside from giving Victoza a running start, the FDA scrutiny could contribute to the idea that Byetta or other GLP-1 drugs are not safe.
Injections that treat diabetes, including insulin and drugs like Victoza from Novo-Nordisk and Byetta from Amylin and Eli Lilly, have had better luck.
By contrast, the Novo Nordisk drug Victoza must be injected daily.
FORBES: And They're Off: Amylin And Novo Nordisk Begin Their Battle
Victoza, a once-daily injectable drug approved two years ago.
WSJ: FDA Approves Amylin's Bydureon Diabetes Drug After Delays
Amylin will try to mitigate Victoza's advantage with pricing.
WSJ: FDA Approves Amylin's Bydureon Diabetes Drug After Delays
Nearly two years after the FDA issued what became the first of two rejections, the agency has finally approved the Bydureon diabetes treatment, setting up what is going to be heated battle between Amylin Pharmaceuticals and Novo Nordisk, which sells a rival medicine called Victoza.
FORBES: And They're Off: Amylin And Novo Nordisk Begin Their Battle
应用推荐